Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Compass Therapeutics (CMPX) over the last 1 years, with Mar 2025 value amounting to $18.5 million.

  • Compass Therapeutics' Gains from Investment Securities rose 63.87% to $18.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $18.5 million, marking a year-over-year increase of 63.87%. This contributed to the annual value of $14.1 million for FY2024, which is 78.54% up from last year.
  • Latest data reveals that Compass Therapeutics reported Gains from Investment Securities of $18.5 million as of Q1 2025, which was up 19,216.67% from $96,000 recorded in Q4 2024.
  • Compass Therapeutics' Gains from Investment Securities' 5-year high stood at $18.5 million during Q1 2025, with a 5-year trough of $96,000 in Q4 2024.
  • For the 3-year period, Compass Therapeutics' Gains from Investment Securities averaged around $7.6 million, with its median value being $7.8 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 39.62% in 2024, then spiked by 63.87% in 2025.
  • Compass Therapeutics' Gains from Investment Securities (Quarterly) stood at $159,000 in 2023, then crashed by 39.62% to $96,000 in 2024, then surged by 63.87% to $18.5 million in 2025.
  • Its Gains from Investment Securities was $18.5 million in Q1 2025, compared to $96,000 in Q4 2024 and $11.3 million in Q1 2024.